Genetic Predictors of Ibrutinib-Related Cardiovascular Side Effects in Patients with Chronic Lymphocytic Leukemia

CONCLUSIONS: Our findings suggest possible genetic determinants of ibrutinib-related CVSEs in CLL. If replicated in a larger study, pre-treatment pharmacogenetic testing for GATA4 and KCNQ1 polymorphisms may be a useful clinical tool for personalizing treatment selection for CLL and/or instituting early risk-mitigation strategies.PMID:37738027 | DOI:10.1158/1078-0432.CCR-23-0421

Source: Clinical Cancer Research - September 22, 2023 Category: Cancer & Oncology Authors: Issam S Hamadeh Jai N Patel Ryan Jacobs Hang Zeng Jiaxian He Bei Hu Tamara Kay Moyo Amy Soni Steven Park Ed Copelan Belinda Avalos Alicia Hamilton Nury Steuerwald Nilanjan Ghosh Source Type: research